



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

5 May 2021

COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
New (1st dose)	62,507	18,942	2,997	2,055	3,113	2,335	2,878	679	353
New (1st dose)	31,159	4,665	2,300	1,673	1,841	1,334	493	348	316
Total (1st)	3,530,014	559,605	222,957	150,241	175,128	111,725	101,009	59,684	17,216
Total (2nd)	298,192	46,290	16,485	12,147	21,556	11,023	7,804	10,936	3,047
	Total	Province							
		Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam
New (1st dose)	10,405	1,322	1,253	1,670	1,576	5,954	3,533	2,602	840
New (1st dose)	5,339	1,636	1,791	773	2,153	1,760	2,543	1,439	755
Total (1st)	767,965	137,758	131,581	174,217	182,202	212,182	229,291	253,679	43,574
Total (2nd)	48,821	17,051	17,019	14,286	17,235	15,826	12,909	17,988	7,769

※ Figures subject to correction recording update

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total	%	General ¹⁾	Anaphylaxis suspected ²⁾	Severe suspected ³⁾	Deaths
Total	New	3,828,206	625	0.47%	614	1	7	3
	Total		18,110		17,769	180	73	88
AstraZeneca	New	1,897,179	471	0.81%	468	1	2	0
	Total		15,364		15,133	145	39	47
Pfizer	New	1,931,027	154	0.14%	146	0	5	3
	Total		2,746		2,636	35	34	41

¹⁾ Mild cases such as headache, fever, nausea, vomiting, etc.

²⁾ Anaphylactoid reaction and anaphylactic shock suspected cases reported by healthcare institutions; Anaphylactoid reaction refers to occurrence of symptoms such as shortness of breath, rashes, etc. within 2 hours of vaccination and differs from anaphylaxis

³⁾ Includes convulsion and other nervous system response and ICU admitted cases

※ Based on the patient's condition at the time of initial report (general, anaphylaxis suspected, severe suspected, death)

※ Cases reported as suspected cases of AEFI; causal association not yet determined; investigation for assessment of causal association to take place for deaths or anaphylaxis cases



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

5 May 2021

Confirmed cases by gender and age group

		New cases (%)		Total cases (%)		Incidence rate* (per 100,000)
Total		676	(100)	124,945	(100)	240.99
Sex	Male	368	(54.44)	62,247	(49.82)	240.68
	Female	308	(45.56)	62,698	(50.18)	241.29
Age	80 or above	14	(2.07)	5,422	(4.34)	285.48
	70-79	35	(5.18)	8,986	(7.19)	249.12
	60-69	102	(15.09)	19,199	(15.37)	302.62
	50-59	116	(17.16)	23,117	(18.50)	266.73
	40-49	117	(17.31)	18,556	(14.85)	221.19
	30-39	105	(15.53)	16,895	(13.52)	239.81
	20-29	98	(14.50)	18,585	(14.87)	273.05
	10-19	57	(8.43)	8,759	(7.01)	177.29
0-9	32	(4.73)	5,426	(4.34)	130.79	

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		7 (100)	1,847 (100)	1.48	173 (100)
Sex	Male	3 (50.00)	917 (49.65)	1.47	106 (61.27)
	Female	4 (66.67)	930 (50.35)	1.48	67 (38.73)
Age	80 or above	5 (83.33)	1,019 (55.17)	18.79	48 (27.75)
	70-79	2 (33.33)	526 (28.48)	5.85	67 (38.73)
	60-69	0 (0.00)	216 (11.69)	1.13	36 (20.81)
	50-59	0 (0.00)	62 (3.36)	0.27	11 (6.36)
	40-49	0 (0.00)	14 (0.76)	0.08	8 (4.62)
	30-39	0 (0.00)	7 (0.38)	0.04	3 (1.73)
	20-29	0 (0.00)	3 (0.16)	0.02	0 (0.63)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.00)
0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)	

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.22.	4.23.	4.24.	4.25.	4.26.	4.27.	4.28.	4.29.	4.30.	5.1	5.2.	5.3.	5.4.	5.5.
Total	125	127	136	136	132	156	160	157	164	174	170	164	162	173

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)